Prosecution Insights
Last updated: April 19, 2026

Examiner: LEVIN, JOEL D

Tech Center 1600 • Art Units: 1600 1633

This examiner grants 51% of resolved cases

Performance Statistics

50.8%
Allow Rate
-9.2% vs TC avg
98
Total Applications
+56.1%
Interview Lift
1613
Avg Prosecution Days
Based on 61 resolved cases, 2023–2026

Rejection Statute Breakdown

4.3%
§101 Eligibility
16.3%
§102 Novelty
40.1%
§103 Obviousness
30.3%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17629286 REGULATABLE EXPRESSION SYSTEMS Final Rejection Novartis AG
16312973 BIO-ELECTRIC NOSE Non-Final OA NORTHWESTERN UNIVERSITY
17369271 METHODS FOR STIMULATING THE PROLIFERATION AND DIFFERENTIATION OF EUKARYOTIC CELLS Non-Final OA PURDUE RESEARCH FOUNDATION
19234245 TREATMENT OF DYSTROPHINOPATHIES WITH MICRODYSTROPHIN GENE THERAPY CONSTRUCTS Final Rejection REGENXBIO INC.
17605207 COMPOSITIONS AND METHODS CHARACTERIZING METASTASIS Final Rejection Dana-Farber Cancer Institute, Inc.
17426566 CELL CULTURE SUBSTRATE Non-Final OA DAI NIPPON PRINTING CO., LTD.
17740102 TARGETED INTEGRATION AT ALPHA-GLOBIN LOCUS IN HUMAN HEMATOPOIETIC STEM AND PROGENITOR CELLS Non-Final OA THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
17777740 MESENCHYMAL STEM CELL DERIVED EXTRACELLULAR VESICLES LOADED WITH AT LEAST ONE PHOTOSENSITIZER AND USES THEREOF FOR THE TREATMENT OF PERITONEAL CARCINOMATOSIS Non-Final OA UNIVERSITÉ PARIS CITÉ
17714593 DONOR ORGAN PRESERVATION USING BOTH STATIC COLD STORAGE AND EX VIVO ORGAN PERFUSION Final Rejection University Health Network
17422646 USE OF MESENCHYMAL STEM CELL SHEETS FOR PREVENTING UTERINE SCAR FORMATION Non-Final OA University of Utah Research Foundation
17382500 CULTURE MEDIA FOR PLURIPOTENT STEM CELLS Non-Final OA Yeda Research and Development Co. Ltd.
17271529 CHIMERIC ANTIGEN RECEPTOR FIBROBLAST CELLS FOR TREATMENT OF CANCER Non-Final OA Figene, LLC
17790052 METHODS AND COMPOSITIONS FOR BINDING IMMUNOGLOBULIN PROTEIN TARGETING Non-Final OA Sanford Burnham Prebys Medical Discovery Institute
17755368 METHODS FOR THE PRODUCTION OF PSILOCYBIN AND INTERMEDIATES OR SIDE PRODUCTS Final Rejection MIAMI UNIVERSITY
17609640 IMPROVED GENE EDITING SYSTEM Final Rejection Suzhou Qi Biodesign biotechnology Company Limited
17776932 METHODS OF CELL SELECTION Non-Final OA LONZA LTD
17292107 PATIENT-DERIVED AMYLOID XENOGRAFT NON-HUMAN ANIMAL MODEL Non-Final OA Neurimmune AG
17292315 PHARMACEUTICAL COMPOSITION CONTAINING PROTEIN KINASE C ACTIVATOR-TREATED STEM CELLS OR CULTURE THEREOF FOR PREVENTING OR TREATING AUTOIMMUNE DISEASES Non-Final OA CORESTEM CO.,LTD.
17825179 METHOD AND DEVICE TO PRESERVE ORGANS AND TISSUE FOR TRANSPLANTATION Final Rejection SoftWave Tissue Regeneration Technologies, Inc.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month